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Abstract
Background: Mexico recently enacted drug policy reform to decriminalize possession of small amounts of illicit
drugs and mandated that police refer identified substance users to drug treatment. However, the economic
implications of drug treatment expansion are uncertain. We estimated the costs of opioid substitution therapy
(OST) provision in Tijuana, Mexico, where opioid use and HIV are major public health concerns.
Methods: We adopted an economic health care provider perspective and applied an ingredients-based micro-costing
approach to quantify the average monthly cost of OST (methadone maintenance) provision at two providers (one private
and one public) in Tijuana, Mexico. Costs were divided by type of input (capital, recurrent personnel and non-personnel).
We defined “delivery cost” as all costs except for the methadone and compared total cost by type of methadone
(powdered form or capsule). Cost data were obtained from interviews with senior staff and review of expenditure
reports. Service provision data were obtained from activity logs and senior staff interviews. Outcomes were cost
per OST contact and cost per person month of OST. We additionally collected information on patient charges for
OST provision from published rates.
Results: The total cost per OST contact at the private and public sites was $3.12 and $5.90, respectively, corresponding
to $95 and $179 per person month of OST. The costs of methadone delivery per OST contact were similar at both sites
($2.78 private and $3.46 public). However, cost of the methadone itself varied substantially ($0.34 per 80 mg dose
[powder] at the private site and $2.44 per dose [capsule] at the public site). Patients were charged $1.93–$2.66 per
methadone dose.
Conclusions: The cost of OST provision in Mexico is consistent with other upper-middle income settings. However,
evidenced-based (OST) drug treatment facilities in Mexico are still unaffordable to most people who inject drugs.
Keywords: Opioid substitution therapy, Methadone, Mexico, Cost
Background
In 2009, the Mexican government passed sweeping drug
policy reforms that decriminalized small amounts of illicit
drug possession for personal consumption and mandated
drug treatment for repeat low-level drug users [1, 2]. Imple-
menting the latter part of the law has been problematic due
to ambiguity on provision of services constituting drug
treatment [1]. Despite the 2009 reforms, drug treatment
and rehabilitation centers are often used to house
drug-dependent individuals [3, 4], many of which are not
federally certified, lack professional staff, and promote
violence [5]. Conversely, expansion of evidence-based drug
treatment programs, such as opioid substitution therapy
(OST), remains largely underdeveloped [6], and the
economic costs of OST expansion in Mexico are unknown.
In addition to numerous societal benefits, such as
reducing crime [7, 8], there is strong evidence support-
ing the role of OST, namely methadone and buprenor-
phine, as effective to treat opioid addiction, reduce HIV
and hepatitis C virus (HCV) transmission, and decrease
overdose-related deaths [9–11]. Both drugs are on the
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World Health Organization’s list of essential medi-
cines [12]. Despite the benefits of these services, the
coverage of OST remains suboptimal. Globally,
approximately 85% of UN member countries reported
low or medium OST coverage (defined as < 40% of
opioid-dependent PWID on OST) in 2014 and a
further 5% of countries reported no coverage of ser-
vices [13]. As opioid use escalates worldwide, scale-up
of these therapies will be an urgent priority. Increas-
ing OST coverage is especially relevant in low/mid-
dle-income countries (LMIC) [14] which have a
majority of the world’s illicit opioid users [15] and
HIV burden [16].
The dual epidemics of injection drug use and HIV along
the US-Mexico border region have been problematic for
over a decade [17]. Tijuana, Mexico, shares the busiest land
border crossing in the world with San Diego, California,
and is an important transit point for trafficking illicit drugs.
Further, Tijuana has one of the highest concentrations of
people who inject drugs (PWID) in Mexico, 4% of whom
are HIV infected and > 90% of whom are hepatitis C virus
antibody positive [18, 19]. Additionally, the most recent es-
timate of 6000–10,000 PWID in Tijuana [17, 20], who are
mostly (62%) male, use heroin daily (90%) and live on less
than 200 USD per month (75%) [21, 22], far outnumbers
the capacity (~ 800 total spaces) at the three OST providers
(two private and one public) currently operating in Tijuana.
The private providers are funded by patient charges, while
the public OST provider receives government subsidies to
cover a substantial portion (> 95%) of its operating budget
with the remaining funds covered by patient charges [23].
Information on costs of harm reduction provision can
provide an evidence base for policymakers when allocating
scarce resources. Most costing analyses of OST facilities
have been conducted in high-income settings with highly
variable estimates, ranging from $3 to $42 per OST patient
per day [24–27]. Provision of OST services has not been
costed in Mexico; however, it is especially needed given
governmental drug policy reform supporting drug treat-
ment expansion [2, 28]. The objective of our analysis is to
measure the average monthly program cost of OST
provision, the cost per OST contact, and the cost per
person month on OST at two providers (private and public)
in Tijuana.
Methods
Data were collected at OST providers located 3–5 km
from the Zona Norte (an area near the US border
that includes the “Red Light District”), which is a hot-
spot of illicit drug activity. Study procedures were ap-
proved by the institutional review boards at UCSD
and Universidad Autónoma de Baja California and all
OST staff provided written informed consent.
Definition of “OST services”
We report on the costs attributable to providing OST
(including “OST-related services,” as defined below), as
well as the cost charged to the patient. As WHO guidelines
for the provision of psychosocially assisted pharmacological
treatment of opioid dependence recommends minimal re-
quirements for the provision of not just pharmacological
treatment but also psychological support and links to
comorbid treatment services [29], we included in our cost-
ing the provision of these ancillary “OST-related” services.
Hence, we included psychosocial support (e.g., cognitive
behavioral therapy, legal advice), HIV and other infectious
disease testing, and referral to HIV care and mental health
services. Rapid urinalysis testing was conducted only at the
public site and performed infrequently. Despite this, we
still obtained data on the annual number of tests con-
ducted and the unit cost. We excluded costs of services
which were not related to this expanded definition of OST
provision or were not provided to these OST patients.
These costs included spirometry, carbon monoxide, preg-
nancy, and hospitalization.
Service provision data collection
Data were collected for year-long costing periods at both
sites (public site: 11/2014–10/2015, private site: 1/2015–
12/2015). Both sites provided the number of unique pa-
tients over the respective costing years and details on
how OST was delivered (e.g., directly observed versus
take-home). At the public site, the number of unique
weekly patients during the costing period was obtained
from interviews with senior staff who referenced written
logs. Eligibility and provision of treatment protocols
were generally similar across both sites and involved
consultations with both physicians and mental health
specialists. However, the public site did include a socio-
economic assessment conducted by a social worker to
determine affordability and cost of OST to the patient.
The number of OST contacts per month was calculated
by summing the number of unique weekday and week-
end contacts per week and multiplying by the average
number of weeks per month. The average number of
OST contacts per month at the private site was based on
review of monthly activity logs.
Costing strategy
We adopted an economic perspective where costs were es-
timated to reflect the real cost of the resources, regardless
of whether they were purchased or donated. We used an
ingredients-based top down (i.e., we did not observe at the
individual client level, instead capturing measured inputs
for the overall OST program [30]) micro-costing approach
to estimate the average monthly cost. We separated “deliv-
ery” costs (personnel, supplies, capital) from the cost of
methadone. Data were collected between November 2015
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and May 2016. Costs were inflated to 2017 Mexican pesos
using the Mexican consumer price index [31] and then
converted to US dollars (USD) using the exchange rate on
January 1, 2017 (20.7 MXN ≈ 1 USD).
Costs were classified as recurrent (i.e., personnel and
non-personnel) and capital. Salaries were taken from ex-
penditure records. Interviews with medical directors were
used to determine employees who were involved with
OST-related tasks, and whether each employee’s role was
solely devoted to OST-related tasks or not. Among those
employees with duties involving both OST-related and
non-OST services, we estimated the fraction of their time
on OST-related tasks from interviews with medical direc-
tors. We cross-checked these estimates with staff diaries
completed by these select employees which documented
the number of hours staff spent OST-related duties over
1 week. Staff reported the activity that was conducted, the
time the activity started and ended, any materials or equip-
ment used, and notes relevant to the activity. Based on
interviews with the senior personnel, volunteer costs
were calculated according to the number of volunteer
OST-related days worked and estimates of daily cost to
hire someone to conduct the same task. Recurrent
non-personnel costs consisted of supplies (including
methadone), federal licensing, utilities, importation fees/de-
livery of methadone, and other services (accounting, main-
tenance, cleaning, security, etc.). Recurrent non-personnel
costs or units used were collected from stock records, pro-
ject accounts, and interviews with personnel. Unit prices
were obtained from financial records, itemized bills/re-
ceipts, and equipment catalogs. Capital costs consisted of
building space and equipment costs. Senior staff provided
the amount paid monthly for rent and an estimate of the
proportion of building space that was attributed only to
provision of OST services, which we confirmed visually
during site visits. Equipment costs were amortized over the
estimated lifespan of the item (furniture and office supplies
10 years, appliances and most medical devices 5 years) and
then converted into a monthly cost.
Outcomes
Outcomes calculated were the average monthly cost of the
program, the cost per OST contact (average monthly costs
divided by the average monthly OST contacts), and cost
per patient month on OST. WHO clinical guidelines rec-
ommend daily dosing of methadone [29]; thus, we esti-
mated the monthly cost of daily OST participation by
multiplying the cost per dose by the average number of
days per month, even though many patients do not attend
daily. We additionally estimate the daily and monthly cost
for “minimal OST provision,” which was the cost of OST
provision excluding HIV, HCV testing, psychosocial coun-
seling, and legal help. In order to ensure comparability of
our estimates between providers, we standardized costs to
an 80-mg dose given the average recommended metha-
done dose of 60–100 mg [32].
Patient charges for OST
We also collected data from senior personnel and pub-
licly available sources on how much the facilities charge
patients for OST, including the clinical evaluation that
they receive prior to initiating methadone.
Results
Study setting and service provision
The private and public sites were open daily and oper-
ated 55 and 50 h per week, respectively. OST provision
was performed as directly observed therapy and
take-home doses were not provided at either site. The
private site offered outpatient services only. It employed
one medical director, three individuals responsible for
methadone dispensing and technical maintenance, one
pharmacist, two physicians, two mental health specialists
(including one psychiatrist and one psychologist), two
lawyers, and five other staff members for administrative
or security related tasks. No group therapy, psycho-
logical counseling services, or HIV/infectious disease
testing was offered, but HIV referral services were avail-
able. The public site offered both outpatient and in-
patient services. The public site had similar staffing (one
medical director, two pharmacists, five psychologists,
one social worker, two administrative personnel, two se-
curity guards, one janitor). Patients were offered psycho-
social services (such as cognitive behavioral therapy or
group counseling). A total of 291 rapid urinalysis tests
were conducted over the entire year. Weekly free HIV
testing and referral services were available at the public
site through a partnership with a local NGO.
Number of patients and contacts with harm reduction
services
The private OST site reported more than twice (N = 450)
the number of unique patients per year compared to the
public OST site (N = 216), yet both sites were estimated
to have similar number of total patient contacts on an
average month (private 2171, public 2128).
Delivery costs (excluding methadone)
Average monthly OST-related personnel costs at the pri-
vate site ($3825) were about two thirds the cost at the
public site ($5979), due to fewer personnel hours devoted
to OST at the private site (Table 1). Substantially, lower
monthly security costs were also found at the private site
($361) compared to the public site ($1174). The delivery
cost per contact (excluding methadone) was roughly simi-
lar, at $2.78 and $3.46 at the private and public sites, re-
spectively. There was a substantial difference in the cost
of the building/space between the private ($1298) and the
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public site ($328). The delivery cost of minimal provision
(excluding HIV, HCV testing, psychosocial counseling,
legal help) was slightly lower at $2.47 and $3.15 at the pri-
vate and public sites, respectively.
Methadone costs
Both sites only provide methadone. The private site pre-
dominantly provides methadone through a suspension
made from powder mixed on site using a dispensing ma-
chine, whereas the public site offers methadone in cap-
sule form. The cost of methadone powder was $0.004
per mg (private site) while the capsule formulation cost
was $0.031 per mg (public site), translating to $0.34 per
80 mg dose via powder formulation at the private site,
and $2.44 per 80 mg dose via capsule at the public site.
Cost of OST provision
Overall, the average cost, including methadone, per OST
contact at the private site ($3.12, powder) was nearly half
the cost at the public site ($5.90, capsule). This was
primarily due to differences in methadone type as de-
scribed above. As shown in Fig. 1, 11% of the costs at
the private site were due to methadone powder, while
methadone capsules constituted 41% of the costs at the
public site. The monthly costs of daily OST participation
at the private and public sites were $95 and $179, re-
spectively. The costs of minimal OST provision (metha-
done only, no associated services) were only slightly
lower at $2.81 and $5.59 per client contact, translating
to $85 and $170 per month of daily OST participation at
the private and public sites, respectively.
Charges and patient services
At the private site, OST charges varied based on dosage,
at $2.66 for a 26–80-mg dose (ranging from $1.69 for 1–
25 mg up to $3.77 for 140–149 mg). Patients were
charged approximately $5 for the initial visit, involving a
clinical evaluation by a physician followed by a consult-
ation with a psychiatrist. At the public site, patients were
charged a flat rate of $1.93 per methadone dose. Initial
visit fee charges were tiered (ranging from $14.50 to
$29) based on a socioeconomic assessment which in-
cluded contributions from the patient and family mem-
bers. The initial visit involved a clinical evaluation and a
diagnostic testing package (HIV and HCV rapid testing,
rapid pregnancy test, urine drug test). If the patient was
on the lowest socioeconomic tier, then the initial visit
fee and diagnostics tests were waived.
Discussion
We found that provision of OST services in Tijuana,
Mexico, had an average cost per OST contact ranging
from $3.12 to $5.90, depending on the type of metha-
done administered. This translates to an average
monthly cost of daily OST provision at $95–$179,
though most patients at these sites attended much less
than daily and did not receive their daily dose. We found
roughly similar OST delivery costs between private and
public OST providers ($2.78–$3.46 per contact) while
the cost of the methadone varied substantially by type,
ranging from $0.34 per 80 mg dose as powder (private
site) to $2.44 per 80 mg as capsule (public site). We note
that although the public provider used capsules, they
opened the capsule and dissolved it in liquid prior to ad-
ministration. Hence, at both clinics, the OST was
ingested as a liquid, suggesting that a patient preference
between the two was unlikely. Based on these results,
providers should consider use of powder methadone,
which would incur an estimated purchase cost of $5800
for the dispensing machine, but provides long-term sav-
ings. OST patient charges for only methadone were
$1.93–2.66 per 80 mg dose.
Our analyses highlight that patient charges may be a
substantial barrier to OST participation among PWID in
Table 1 Capacity and average monthly costs for private and
public OST sites in Tijuana, Mexico, in 2017 USD
Private Public
Unit of service
Patient contacts on methadone per month 2171 2128
Costs (USD) (monthly)
Personnel (recurrent) 3825 5979
Director 226 878
Physician/medical director 790 1125
Pharmacist/methadone dispensing technicians 1076 1856
Mental health specialist (psychiatrist or
psychologist)
230 270
Social worker/lawyer 452 106
Administrative personnel 226 474
Accountant 397 –
Security guard 361 1174
Janitor 68 96
Non-personnel (recurrent) 865 760
Utilities and other services 555 436
Licensing 37 37
Supplies 273 287
Capital 1357 622
Building/space 1298 328
Equipment 59 294
Cost of methadone delivery 6047 7685
Cost of methadone 731 5195
Cost per OST contact (delivery only) 2.78 3.46
Cost per OST contact (methadone only) 0.34 2.44
Total cost of OST contact 3.12 5.90
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Tijuana. The cost of the initial clinical evaluation, admis-
sion, and daily cost of an average dose of methadone
(approximately $58–$81 for 80 mg dose per month) may
be unaffordable to average PWID in Tijuana, among
whom nearly 75% reported earning less than $211 per
month [33]. We note that the cost of an average dose of
heroin is approximately $1.30 [34]. However, nearly 75%
PWID in Tijuana inject more than once per day [35],
suggesting that their daily heroin cost may be similar to
their OST cost.
Numerous additional logistical and economic barriers
limit the accessibility of OST providers for the PWID
population in Tijuana, where < 8% of PWID report acces-
sing OST in the past 6 months [36]. Transport to the sites
may be problematic for many PWID who reside in the
Zona Norte since the sites are located approximately 3–
5 km away, and many PWID do not have reliable trans-
portation [37]. No take home doses are provided to local
patients. Importantly, we noted that the number of pa-
tients differed between the two sites (lower at the public
site), but the number of monthly contacts were similar, in-
dicating higher levels of patient attendance at the public
site. It is unclear what is driving this difference in attend-
ance, which could be due to a number of external factors
and provider factors. The private clinic is located in a re-
gion of the city with a higher concentration of patients
with substance use disorders than the public clinic. The
greater police presence in the area near the private clinic
and frequent “police sweeps” occasionally threatens dis-
ruption of their maintenance treatment [22]. Conversely,
although the public site is located further away from the
area of high drug use, the many additional ancillary ser-
vices offered by the public site, such as group and individ-
ual counseling sessions, may help ensure regular
attendance. Future work should examine the structural,
provider, and patient characteristics to inform a deeper
understanding of ideal models of care.
Economic and political barriers also threaten retention in
methadone programs, since structural factors such as arbi-
trary policing and bribery near methadone sites threaten
the economic stability of patients [36, 38]. These factors
may contribute to patients having missed their daily doses.
Previous studies have found that poor methadone retention
has been associated with relapse [39], criminal behavior
[40], and overdose [11]. Based on the number of unique pa-
tients per year and total patient contacts per month, this
equated to approximately 5–10 contacts per unique patient
per month; however, not all patients were in the OST pro-
gram for the entire year. Despite this, we have recently
trained over 1800 police officers on the benefits of harm re-
duction [41]. We are currently evaluating how the police
training may have improved attitudes towards OST and de-
creased arrests near these sites.
Our study is the first to provide an estimate on the
cost of OST provision in a Latin American setting and
has important implications for the Mexican drug policy
reforms passed in 2009 which sought to expand drug
treatment as an alternative to incarceration for low level
offenders [28]. As mentioned, few PWID in Tijuana ac-
cess OST given the barriers described above. Addition-
ally, and unfortunately, various “drug treatment”
facilities exist in Tijuana [42], and funding has been
diverted to non-evidence based compulsory detention fa-
cilities marketing themselves under the guise of drug
treatment clinics and rehabilitation centers, including
some that have a history of mistreating patients [3]. The
source of financing is especially relevant in Mexico
where a 2002 law stipulated that economic profits from
drug seizures were to be partially reallocated to the Sec-
retariat of Health in Mexico to fund drug prevention
Fig. 1 Breakdown of the cost per OST contact (2017 USD) at two OST providers (one private, one public) in Tijuana Mexico
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and rehabilitation programs [43]. However, it is un-
known how much of this supports OST programs.
Promisingly, the high quality of the evidence-based OST
programs evaluated in this study was reflected by service
provision of qualified personnel. At the public site, the
social worker had a bachelor’s degree equivalency and
the psychologists had bachelor’s degrees in psychology
and master’s degrees degree in family counseling [44].
The private site reported similar staff credentials. The
diverse staff that included clinicians, mental health spe-
cialists, and social workers/legal experts, suggests that
patients could receive comprehensive opioid treatment
services, as recommended by the WHO [12].
Comparisons with published literature
To our knowledge, there are no other published reports
of OST provision cost in Latin America. Our costs per
contact ranging from $3.12 to 5.90 were lower than in
high-income countries, but higher than other LMIC
(Table 2). For example, a study from Vietnam reported
that the average cost per methadone contact was $1.01
($1.18 in 2017) at a 40-mg dose [45], compared to an es-
timated $2.95 in Tijuana using a 40-mg powder dose.
This discrepancy may be partly explained by lower
wages. However, our estimates were also higher com-
pared to other upper-middle income countries such as
China, which reported that methadone maintenance fa-
cilities charge patients approximately $1.50 per patient
per day to cover program costs [46, 47]. Finally, our esti-
mate was in the lower range of published estimates from
high-income studies. For example, in Europe, costs
ranged from 3.14 EUR ($3.42 in 2017) to 38.70 EUR
($42.09 in 2017) per OST patient visit [48]. A costing
analysis conducted among 159 methadone providers in
the USA found that the average cost per patient visit
was $11.53 ($16.24 in 2017) [49], similar to Ontario,
Canada ($15.48 CAD in 2010 or approximately $13.83
USD in 2017) [50]. Per patient monthly methadone
treatment costs in high-income settings range between
$400 and $550 which is more than double the cost in
upper-middle income settings like Mexico. Assuming
daily attendance, the cost per patient month was similar
to OST patient-month costs in Lithuania ($174 per pa-
tient month, after adjusting to 2017 USD) [51].
Limitations
Although we collected information on the amount
charged for methadone, we did not perform our cost
analysis from a societal perspective because we were un-
able to capture any other participant costs or societal
benefits. Since we did not have patient level data, we
could not explore the financial cost of transportation to/
from the OST site, unpaid time taken off work, and po-
tential benefits of OST such as reduced criminal justice
interactions [40], and prevention of HIV/HCV [9, 52]
and other health benefits. Such information (steady em-
ployment, criminal justice involvement, co-morbidities)
would provide a more comprehensive estimate of the
full economic costs of OST provision. We also did not
have access to patient-level data. This precluded us from
differentiating patients who were active and former
PWID, who may have incurred different treatment costs.
Additionally, we could not estimate the number of
missed doses and the OST retention rate which are im-
portant since frequency of visits and duration of treat-
ment would likely affect costs. However, unpublished
findings from our ongoing cohort of active and former
PWID suggest that among all study visits of PWID who
were currently on OST, only 23% of those visits were
followed by a consecutive visit on OST 6 months later,
indicating low levels of retention. Short duration of OST
has been found in other settings, such as the UK, where
Table 2 Average daily and monthly per patient monthly costs among various country income levels
Country World Bank income classification Daily OST cost (2017 USD) per patient Monthly OST cost (2017 USD) per patient* Reference
Mexico Upper-middle income 3.12–5.90 95–179 Present study
Canada High income 17.34 527 [55]
Canada High income 13.83 420 [50]
UK High income 13.22 402 [56]
USA High income 15.52 472 [57]
USA High income 14.24 433 [58]
Lithuania High income 5.72 174 [51]
Iran Upper-middle income 3.65 111 [59]
China Upper-middle income 0.33–0.56 9–17 [60]
Malaysia Upper-middle income 1.66 50 [61]
Indonesia Lower-middle income 1.31 40 [62]
Vietnam Lower-middle income 1.17 36 [45]
*Assuming daily visits
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less than 50% were retained at 6 months [53]. However,
longer periods on OST have been reported in settings
with higher thresholds for entry or more restrictive
treatment availability [54]. Infrequent attendance likely
increases the cost of OST provision due to higher per
contact overhead costs, and as such achieving enhanced
retention could reduce the cost of OST provision.
Conclusions
We found comprehensive OST provision in Tijuana,
Mexico, at a cost of around $3 per contact. However,
coverage is hampered by structural barriers and patient
charges which may be unaffordable to most PWID. Our
results are particularly timely in Mexico given recent
drug policy reforms, which aim to expand access to drug
treatment provision. Lowering methadone charges may
help increase accessibility and affordability for PWID in
Tijuana.
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